CGTX

CGTX

Cognition Therapeutics Inc

Net 28.58%top 1%Rev โ€”top 1%Net income grew 100% of years1Y
Hold

Cognition Therapeutics develops small molecule therapeutics aimed at age-related neurological disorders. Its lead candidate, zervimesine, targets Alzheimer's disease, Mild Cognitive Impairment, and other conditions affecting synaptic health.

โš•๏ธ Healthcare NASDAQ Listed 2021 $ USD
$1,000 invested 1 year ago โ†’$945today

Score Overview

1 Year
Scoreโ€”
Net Growth28.58%
Net TrendGrew
Net Income Consistencyโ€”
Rev Growthโ€”
Rev TrendShrank
Revenue Consistencyโ€”
All Time
Scoreโ€”
Net Growth-43.18%
Net Trend60%
Net Income Consistency
Rev Growthโ€”
Rev TrendNever
Revenue Consistency

See the full market ranking โ†’

Cognition Therapeutics Inc fundamental performance

Across Cognition Therapeutics Inc's full reported history, from 2021 to 2025, revenue held from $ 0.00 to $ 0.00 and net income went from -$ 11M to -$ 23M. Revenue increased in 0% of the years measured; net income in 60%.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-08-12
$ 1.04โ€”
1 Year2025-08-12
$ 1.10-5.45%
All Time2021-10-08
$ 12.77-91.86%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Year
2026$ 0.00-$ 16M$ 34M
2025$ 0.00-$ 23M$ 36M
2024$ 0.00-$ 33M$ 25M
2023$ 0.00-$ 25M$ 29M
2022$ 0.00$ 757K$ 41M
IPO2021$ 0.00-$ 11M$ 54M

Explore beyond CGTX

You're looking at Cognition Therapeutics Inc. Members apply the same fundamental framework across all 3,860 companies we cover.

$99/year $149 founding price

Unlock Holder Dashboard

30-day money-back guarantee.

Explore other companies